Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.47 USD | 0.00% | -6.16% | +522.50% |
Jun. 04 | Maxim Downgrades ZIVO Bioscience to Hold From Buy | MT |
May. 13 | ZIVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 296K | Sales 2025 * | 1.51M | Capitalization | 24.49M |
---|---|---|---|---|---|
Net income 2024 * | -5M | Net income 2025 * | -5M | EV / Sales 2024 * | 82.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 16.2 x |
P/E ratio 2024 * |
-4.55
x | P/E ratio 2025 * |
-6.23
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.32% |
1 week | -6.16% | ||
Current month | -6.16% | ||
1 month | -4.60% | ||
3 months | -16.54% | ||
6 months | +703.23% | ||
Current year | +522.50% |
Managers | Title | Age | Since |
---|---|---|---|
John Payne
CEO | Chief Executive Officer | 76 | 13-07-18 |
Keith Marchiando
DFI | Director of Finance/CFO | 61 | 20-12-31 |
Laura Belicka
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nola Masterson
BRD | Director/Board Member | 77 | 14-09-16 |
Director/Board Member | 58 | 13-08-27 | |
John Payne
CEO | Chief Executive Officer | 76 | 13-07-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 7.47 | 0.00% | 554 |
24-06-07 | 7.47 | 0.00% | 235 |
Delayed Quote OTC Markets, June 10, 2024 at 02:12 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+522.50% | 24.49M | |
+10.73% | 7.96B | |
+3.46% | 7.48B | |
-0.58% | 5.88B | |
-7.22% | 3.67B | |
-13.21% | 3.47B | |
-15.49% | 1.16B | |
-25.03% | 1.14B | |
+9.98% | 948M | |
-12.57% | 893M |
- Stock Market
- Equities
- ZIVO Stock